Cytokine Production and Treatment Response in Major Depressive Disorder

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Neuropsychopharmacology

• Publication date

  2000-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0893-133X(99)00134-7PMID 10700656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

  2008cited by this paper
• Dose-dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune-endocrine host response in humans

  1999cited by this paper
• Circulating Lymphocyte Subsets in Major Depression and Dysthymia With Typical or Atypical Features

  1998cited by this paper
• Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders.

  1998cited by this paper
• An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat.

  1998cited by this paper
• Depression, stress and immunological activation: the role of cytokines in depressive disorders.

  1998cited by this paper
• Blood levels of cytokines in elderly patients with major depressive disorder

  1998cited by this paper
• Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

  1997influential reference
• Acute phase proteins in major depression.

  1997cited by this paper
• SKID. Strukturiertes Klinisches Interview für DSM-IV. Achse I und II. Handanweisung

  1997cited by this paper
• Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells

  1996cited by this paper
• Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells.

  1996cited by this paper
• Major depressive disorder is associated with elevated monocyte counts

  1996influential reference
• Indicators of immune activation in major depression.

  1996influential reference
• Interleukin‐6 Serum Levels in Depressed Patients before and after Treatment with Fluoxetine

  1995influential reference
• Cytokine Production and Serum Proteins in Depression

  1995cited by this paper
• Evidence for an immune response in major depression: a review and hypothesis.

  1995influential reference
• Increased serum interleukin-1-receptor-antagonist concentrations in major depression.

  1995cited by this paper
• Increased levels of alpha‐1‐acid glycoprotein and interleukin‐6 in refractory depression

  1995cited by this paper
• Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.

  1995influential reference
• Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response.

  1994cited by this paper
• Cytokine production in major depressed patients before and after clomipramine treatment.

  1994cited by this paper
• Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?

  1993cited by this paper
• Novel method for the measurement of cytokine production by a one-stage procedure.

  1993cited by this paper
• Neutrophil and monocyte phagocytosis in depressed patients.

  1993influential reference
• Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression.

  1992cited by this paper
• Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production

  1991cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Interleukin-6 Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Major Depressive Disorder in a Tertiary Care Center

  2026cites this paper
• Research Progress on the Mechanism of Acupuncture in Treating Depression by Regulating Hippocampal Neuroinflammation via the Microbiota-Gut-Brain Axis

  2026cites this paper
• Assessment and Comparison of Markers of Inflammation and the Systemic Immune–Inflammation Index in Patients with Major Depressive Disorder and Healthy Controls at SMS Medical College, Jaipur: An Observational Case–Control Study

  2026cites this paper
• Inflammatory and MRI perfusion biomarkers in predicting persistence of depression: a 6-month Longitudinal Study

  2025cites this paper
• Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression.

  2025cites this paper
• Combination Therapy Against Mood and Anxiety Disorders: Association Between Efficacy and White Blood Cell Count

  2025cites this paper
• TMEM119-Defined brain Macrophage phenotypes in a chronic stress model induced by corticosterone in Male mice.

  2025cites this paper
• Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment

  2025cites this paper
• The role of cytokines in predicting the therapeutic effect of non-suicidal self-injury in adolescents: a longitudinal study

  2025cites this paper
• Chronic stress, gut microbiota, and immunity: interconnections and implications for health

  2025cites this paper
• Folate supplementation as a beneficial add‐on treatment in relieving depressive symptoms: A meta‐analysis of meta‐analyses

  2024cites this paper
• Structural and functional brain correlates of the neutrophil- and monocyte-to-lymphocyte ratio in neuropsychiatric disorders

  2024cites this paper
• Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

  2024cites this paper
• Biomarkers of stress resilience: A review

  2024cites this paper
• Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.

  2024cites this paper
• Low Hemoglobin Level and Elevated Inflammatory Hematological Ratios Associated With Depression and Sleep Disturbance

  2024cites this paper
• Low-grade inflammation and serotonin 4 receptor binding in the healthy and the depressed brain

  2024cites this paper
• Chronic Rhinosinusitis and Mental Health.

  2024cites this paper
• Pharmaceutical-mediated neuroimmune modulation in psychiatric/psychological adverse events.

  2024cites this paper
• The Neurodegenerative Hypothesis of Depression and the Influence of Antidepressant Medications.

  2024cites this paper
• Associations of Depression, Antidepressants with Atrial Fibrillation Risk in HFpEF Patients

  2024cites this paper
• Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial

  2024cites this paper
• Human olfactory neural progenitor cells reveal differences in IL-6, IL-8, thrombospondin-1, and MCP-1 in major depression disorder and borderline personality disorder

  2024cites this paper
• Inflammation in obsessive–compulsive disorder: A literature review and hypothesis‐based potential of transcranial photobiomodulation

  2024cites this paper
• Association Between Mood Disorder Severity, Treatment Response and Systemic Inflammatory Markers: Exploring the Role of NLR, PLR, MLR, and SII

  2024cites this paper
• The inflammatory underpinning of depression: An historical perspective.

  2024cites this paper
• Inflammatory Biomarker Findings from a Randomized Controlled Trial of Heated Yoga for Depression

  2024cites this paper
• The role of polyunsaturated fatty acids in the neurobiology of major depressive disorder and suicide risk

  2023cites this paper
• Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface.

  2023cites this paper
• High-sensitivity C-reactive protein is a predictor of depression in patients with mild traumatic brain injury.

  2023cites this paper
• Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health

  2023cites this paper
• Biological correlates of treatment resistant depression: a review of peripheral biomarkers

  2023cites this paper
• Global Research Trends and Hotspots Analysis of the Scientific Production of Amitriptyline: A Bibliometric Approach

  2023cites this paper
• Chemokine receptor 5 signaling in PFC mediates stress susceptibility in female mice

  2023cites this paper
• DEPRESSION AS A DYSFUNCTION OF IMMUNE SYSTEM: A REVIEW

  2023cites this paper
• Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies

  2023cites this paper
• White matter integrity and pro-inflammatory cytokines as predictors of antidepressant response in MDD.

  2023cites this paper
• Blocking osteopontin expression attenuates neuroinflammation and mitigates LPS-induced depressive-like behavior in mice.

  2023cites this paper
• Peripheral inflammatory markers in melancholic versus non-melancholic depression.

  2023cites this paper
• Suicide Risk in Rheumatoid Arthritis Patients is Associated With Suboptimal Vitamin D Levels

  2022cites this paper
• C1q deletion exacerbates stress-induced learned helplessness behavior and induces neuroinflammation in mice

  2022cites this paper
• Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder

  2022cites this paper
• How does IL-6 change after combined treatment in MDD patients? A systematic review

  2022cites this paper
• Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity

  2022cites this paper
• Anti-Inflammatory Action of Antidepressants: Investigating the Longitudinal Effect of Antidepressants on White Blood Cell Count

  2022cites this paper
• Fluoxetine Decreases Phagocytic Function via REV-ERBα in Microglia

  2022influential citation
• Elevated C-reactive protein-to-albumin ratio with fever is a predictor of poor functional outcome in patients with mild traumatic brain injury

  2022cites this paper
• Effect of quetiapine on inflammation and immunity: a systematic review

  2022cites this paper
• Potential mechanisms underlying the accelerated cognitive decline in people with chronic low back pain: A scoping review.

  2022cites this paper
• Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression.

  2022cites this paper
• Importance of immunometabolic markers for the classification of patients with major depressive disorder using machine learning.

  2022cites this paper
• Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors

  2022cites this paper
• Is depression the missing link between inflammatory mediators and cancer?

  2022cites this paper
• Exploring the role of biologics in depression.

  2022cites this paper
• Attenuation of the levels of pro-inflammatory cytokines prevents depressive-like behavior during ethanol withdrawal in mice.

  2022cites this paper
• Association Between Depressive Symptoms and Cardiac Structure and Function in a Peruvian Population

  2022cites this paper
• C-reactive protein could predict the efficacy of SSRIs in clinical practice: A cohort study of large samples in the real world.

  2022cites this paper
• Repurposing Anti-inflammatory Agents for Mood Disorders: an Updated Review of Current Evidence

  2022cites this paper
• Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

  2022cites this paper
• The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial

  2022cites this paper
• Fibromyalgia and Depression: A Literature Review of Their Shared Aspects

  2022cites this paper
• Stress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders.

  2022cites this paper
• Differential effects of lipopolysaccharide on cognition, corticosterone and cytokines in socially-housed vs isolated male rats.

  2022cites this paper
• Inflammatory Biomarker and Response to Antidepressant in Major Depressive Disorder: a Systematic Review and Meta-Analysis.

  2022cites this paper
• Associations between Heart Rate Variability, Peripheral Inflammatory Markers and Major Depressive Disorder.

  2022cites this paper
• Earlier age of onset is associated with a pro-inflammatory state in major depressive disorder.

  2022cites this paper
• The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol

  2022cites this paper
• Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.

  2022cites this paper
• Association of Depression, Antidepressants With Atrial Fibrillation Risk: A Systemic Review and Meta-Analysis

  2022cites this paper
• Depression, Anxiety, and Quality of Life in Patients Treated with Single Infusion Tocilizumab for COVID-19: A Follow-up, Controlled Study

  2022cites this paper
• Inflammation and Blood-Brain Barrier in Depression: Interaction of CLDN5 and IL6 Gene Variants in Stress-Induced Depression

  2022cites this paper
• The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis

  2022cites this paper
• Update on the Relationship Between Depression and Neuroendocrine Metabolism

  2021cites this paper
• Mental health of patients suffering from connective tissue diseases. Negative and positive concept and selected correlates.

  2021cites this paper
• Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer’s Disease: The Role of Antioxidants in Prevention and Treatment

  2021cites this paper
• SIGIRR and TNFAIP3 Are Differentially Expressed in Both PBMC and TNF-α Secreting Cells of Patients With Major Depressive Disorder

  2021cites this paper
• C-reactive protein as a potential biomarker in psychiatric practice: Are we there yet?

  2021cites this paper
• Biomarkers of Post-COVID Depression

  2021cites this paper
• Interleukin-8 and lower severity of depression in females, but not males, with treatment-resistant depression.

  2021cites this paper
• Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression

  2021cites this paper
• Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review

  2021cites this paper
• Chemokines as Potential Biomarkers for PTSD in Military Population

  2021cites this paper
• IL-6, sTNF-R2, and CRP in the context of sleep, circadian preference, and health in adolescents with eveningness chronotype: Cross-sectional and longitudinal treatment effects.

  2021cites this paper
• Perinatal depression prevention through the mother-infant dyad: The role of maternal childhood maltreatment.

  2021cites this paper
• Disease trajectories and mortality among individuals diagnosed with depression: a community-based cohort study in UK Biobank

  2021cites this paper
• The association between depression and chronic lower back pain from disc degeneration and herniation of the lumbar spine

  2021cites this paper
• Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers

  2021cites this paper
• Association between high-sensitivity C-reactive protein levels and depression: Moderation by age, sex, obesity, and aerobic physical activity.

  2021cites this paper
• On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?

  2021cites this paper
• Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders

  2021cites this paper
• Diffusion-weighted MR Spectroscopy (DW-MRS) is sensitive to LPS-induced changes in human glial morphometry: A preliminary study.

  2021cites this paper
• The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment

  2021cites this paper
• Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients.

  2021cites this paper
• The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill

  2021cites this paper
• Special Report

  2021cites this paper
• Inflammation and Cognition in Depression: A Narrative Review

  2021cites this paper
• Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression.

  2021cites this paper
• A Review of the Role of Interleukin-2 in the Pathophysiology of Major Depressive Disorder in Hospitalized Patients

  2021cites this paper
• Peripheral biomarkers in major depressive disorders

  2021cites this paper
• Ion Channel Dysfunction and Neuroinflammation in Migraine and Depression

  2021cites this paper